Melt up. That's what they call it when the market goes up every day as it did this week, hitting more new highs than a pothead who won Powerball. The rotations between sectors have become less violent not to say that there aren't laggards or choices to be made. Financials, particularly banks and investment banks, continue to lead but on any given day it can be transports or industrials or metals – well, you get the picture. Health care, on the other hand, had a bit of a headwind after President-elect Donald Trump was quoted in Time Magazine reiterating his issues with drug prices. This is a sector that will continue to be under assault, trading opportunities aside, because it has everything that Trump dislikes: The pharma industry spends more on lobbying than any other industry by a wide margin; Medicare, arguably the single largest customer of prescription drugs in the world, is prohibited from negotiating prices under Obamacare; a number of pharma companies had already located offshore prior to the law changing; and the same prescriptions cost more in the U.S. than in other countries, i.e., Gilead's Sovaldi regimen is $10,000 in some regions versus $90,000 here. In other words, you can date Lilly and Pfizer but don't get hitched.